keyword
MENU ▼
Read by QxMD icon Read
search

Sanfilippo syndrome

keyword
https://www.readbyqxmd.com/read/27857809/delayed-speech-hyperactivity-and-coarse-facies-does-sanfilippo-syndrome-come-to-mind
#1
Ayşe Kartal
Mucopolysaccharidosis Type IIIA (MPS IIIA) or Sanfilippo-A syndrome is caused by a deficiency in lysosomal a-heparan N-sulfatase. Its clinical manifestations include progressive dementia, hyperactivity, and aggressive behavior. Unlike other mucopolysaccharide disorders, the diagnosis of MPS IIIA is challenging in both adults and children. This diagnostic challenge has been associated with the high incidence of false negative results encountered on urinary screening tests. We herein describe Sanfilippo-A syndrome in a pediatric patient who presented with progressive hyperactivity, delayed language, and developmental delay and a negative urine screening test...
July 2016: Journal of Pediatric Neurosciences
https://www.readbyqxmd.com/read/27832416/slow-continuous-enzyme-replacement-via-spinal-csf-in-dogs-with-the-paediatric-onset-neurodegenerative-disease-mps-iiia
#2
Barbara King, Neil R Marshall, Sofia Hassiotis, Paul J Trim, Justin Tucker, Kathryn Hattersley, Marten F Snel, Robert D Jolly, John J Hopwood, Kim M Hemsley
Intra-cerebrospinal fluid (CSF) injection of recombinant human lysosomal enzyme is a potential treatment strategy for several neurodegenerative lysosomal storage disorders including Sanfilippo syndrome (Mucopolysaccharidosis type IIIA; MPS IIIA). Here we have utilised the MPS IIIA Huntaway dog model to compare the effectiveness of the repeated intermittent bolus injection strategy being used in the trials with an alternate approach; slow, continual infusion of replacement enzyme (recombinant human sulphamidase; rhSGSH) into the spinal CSF using a SynchroMed II® pump attached to a spinal infusion cannula...
November 10, 2016: Journal of Inherited Metabolic Disease
https://www.readbyqxmd.com/read/27827379/kl%C3%A3-ver-bucy-syndrome-associated-with-a-recessive-variant-in-hgsnat-in-two-siblings-with-mucopolysaccharidosis-type-iiic-sanfilippo-c
#3
Hao Hu, Christoph Hübner, Zoltan Lukacs, Luciana Musante, Esther Gill, Thomas F Wienker, Hans-Hilger Ropers, Ellen Knierim, Markus Schuelke
Klüver-Bucy syndrome (KBS) comprises a set of neurobehavioral symptoms with psychic blindness, hypersexuality, disinhibition, hyperorality, and hypermetamorphosis that were originally observed after bilateral lobectomy in Rhesus monkeys. We investigated two siblings with KBS from a consanguineous family by whole-exome sequencing and autozygosity mapping. We detected a homozygous variant in the heparan-α-glucosaminidase-N-acetyltransferase gene (HGSNAT; c.518G>A, p.(G173D), NCBI ClinVar RCV000239404.1), which segregated with the phenotype...
November 9, 2016: European Journal of Human Genetics: EJHG
https://www.readbyqxmd.com/read/27733599/natural-history-of-sanfilippo-syndrome-type-c-in-boyac%C3%A3-colombia-a-neurogenetic-description
#4
Harvy Mauricio Velasco, Yasmin Sanchez, Angela Milena Martin, Luis A Umaña
Mucopolysaccharidosis type III, or Sanfilippo syndrome, is an autosomal recessive disorder characterized by impairment in the degradation of Heparan sulfate. Here the authors describe the natural history of 5 related individuals; all associated through a large pedigree which reports a total of 11 affected members, originally from the Boyacá region in Colombia, diagnosed with MPS IIIC who all harbor a novel mutation in HGSNAT The authors report an unusually high incidence of the disease in this population. The clinical features are similar to previously described patients, although some differences in the degree of severity and end-stage of the disease are seen in this specific group...
October 12, 2016: Journal of Child Neurology
https://www.readbyqxmd.com/read/27636868/external-genitalia-hypertrophy-in-an-adolescent-girl-with-sanfilippo-syndrome
#5
Flora Bacopoulou, Despoina Apostolaki, Roser Pons
OBJECTIVE: To report unusual gynaecological features associated with Sanfilippo syndrome, a rare progressive multisystem storage disorder. CASE: A 10-year-old adolescent girl with Sanfilippo syndrome type B, presented to the Center for Adolescent Medicine accompanied by her mother. Maternal anxiety was related to a palpable mass over the adolescent's external genitalia that had been causing her discomfort and exacerbation of her behavioural problems when wearing trousers...
October 2016: European Journal of Contraception & Reproductive Health Care
https://www.readbyqxmd.com/read/27568297/turner-syndrome-have-you-thought-about-fertility
#6
EDITORIAL
Joseph S Sanfilippo
No abstract text is available yet for this article.
October 2016: Journal of Pediatric and Adolescent Gynecology
https://www.readbyqxmd.com/read/27489053/secondary-preventive-medication-use-in-a-prevalent-population-based-cohort-of-acute-coronary-syndrome-survivors
#7
Anthony S Gunnell, Joseph Hung, Matthew W Knuiman, Lee Nedkoff, Malcolm Gillies, Elizabeth Geelhoed, Michael S T Hobbs, Judith M Katzenellenbogen, Jamie M Rankin, Michael Ortiz, Tom G Briffa, Frank M Sanfilippo
AIM: Describe the dispensing patterns for guideline-recommended medications during 2008 in people with acute coronary syndrome (ACS) and how dispensing varies by gender and time since last ACS hospitalization. METHOD: A descriptive cohort spanning 20 years of people alive post-ACS in 2008. We extracted all ACS hospitalizations and deaths in Western Australia (1989-2008), and all person-linked Pharmaceutical Benefits Scheme claims nationally for 2008. Participants were 23 642 men and women (36...
December 2016: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/27452122/hgsnat-has-a-tata-less-promoter-with-multiple-starts-of-transcription
#8
Eva Richtrova, Lenka S Mrazova, Dita Musalkova, Ondrej Luksan, Larisa Stolnaya, Jakub Minks, Jan Lukas, Lenka Dvorakova, Milan Jirsa, Martin Hrebicek
Acetyl-CoA:α-glucosaminide N-acetyltransferase (N-acetyltransferase) is a lysosomal membrane enzyme that catalyzes a key step in the lysosomal degradation of heparan sulfate. Its deficiency causes Sanfilippo syndrome type IIIC (Mucopolysaccharidosis type IIIC, MPS IIIC). Here we characterize the promoter region of HGSNAT, the gene encoding N-acetyltransferase, which is located in the pericentromeric region of chromosome 8. We show that HGSNAT transcription is driven by a TATA-less promoter whose key elements are contained within the 1054bp region upstream of exon 1...
October 30, 2016: Gene
https://www.readbyqxmd.com/read/27340089/behavioral-deficits-and-cholinergic-pathway-abnormalities-in-male-sanfilippo-b-mice
#9
Shih-Hsin Kan, Steven Q Le, Quang D Bui, Braeden Benedict, Jesse Cushman, Mark S Sands, Patricia I Dickson
Sanfilippo B syndrome is a progressive neurological disorder caused by inability to catabolize heparan sulfate glycosaminoglycans. We studied neurobehavior in male Sanfilippo B mice and heterozygous littermate controls from 16 to 20 weeks of age. Affected mice showed reduced anxiety, with a decrease in the number of stretch-attend postures during the elevated plus maze (p=0.001) and an increased tendency to linger in the center of an open field (p=0.032). Water maze testing showed impaired spatial learning, with reduced preference for the target quadrant (p=0...
October 1, 2016: Behavioural Brain Research
https://www.readbyqxmd.com/read/27324169/the-multifacets-of-androgen-insensitivity-syndrome
#10
EDITORIAL
Joseph S Sanfilippo
No abstract text is available yet for this article.
August 2016: Journal of Pediatric and Adolescent Gynecology
https://www.readbyqxmd.com/read/27100513/glycosaminoglycans-and-mucopolysaccharidosis-type-iii
#11
Joanna Jakobkiewicz-Banecka, Magdalena Gabig-Ciminska, Anna Kloska, Marcelina Malinowska, Ewa Piotrowska, Zyta Banecka-Majkutewicz, Bogdan Banecki, Alicja Wegrzyn, Grzegorz Wegrzyn
Mucopolysaccharidosis type III (MPS III), or Sanfilippo syndrome, is a lysosomal storage disease in which heparan sulfate is accumulated in lysosomes, as well as outside of cells, as the primary storage material. This disease is a complex of four conditions caused by dysfunctions of one of genes coding for lysosomal enzymes involved in degradation of heparan sulfate: SGSH (coding for heparan N-sulfatase) - causing MPS IIIA, NAGLU (coding for alpha-N-acetylglucosaminidase) - causing MPS IIIB, HGSNAT (coding for acetyl CoA alpha-glucosaminide acetyltransferase) - causing MPS IIIC), and GNS (coding for N-acetylglucosamine-6-sulfatase) - causing MPS IIID...
2016: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/27071779/corrigendum-to-alteration-of-cerebral-iron-metabolism-in-sanfilippo-syndrome-mol-genet-metab-117-2-february-2016-p-597
#12
Vincent Puy, Pierre-Edouard Bodet, Camille Rottier, Rémi Delaunay, Cathy Gomila, Ahmed Hodroge, Liliane Rackowski, Thibaud Lefebvre, Zoubida Karim, Sandrine Vitry, Florence Gonnet, Régis Daniel, Jerome Ausseil, Chester B Whitley
No abstract text is available yet for this article.
May 2016: Molecular Genetics and Metabolism
https://www.readbyqxmd.com/read/27014573/preferred-transduction-with-aav8-and-aav9-via-thalamic-administration-in-the-mps-iiib-model-a-comparison-of-four-raav-serotypes
#13
J A Gilkes, M D Bloom, C D Heldermon
Sanfilippo syndrome type B (MPS IIIB) is a lysosomal storage disease caused by a deficiency of N-acetyl-glucosaminidase (NAGLU) activity. Since early therapeutic intervention is likely to yield the most efficacious results, we sought to determine the possible therapeutic utility of rAAV in early gene therapy based interventions. Currently, the application of recombinant adeno-associated virus (AAV) vectors is one of the most widely used gene transfer systems, and represents a promising approach in the treatment of MPS IIIB...
March 2016: Molecular Genetics and Metabolism Reports
https://www.readbyqxmd.com/read/26975339/a-preclinical-study-evaluating-aavrh10-based-gene-therapy-for-sanfilippo-syndrome
#14
Leanne K Winner, Helen Beard, Sofia Hassiotis, Adeline A Lau, Amanda J Luck, John J Hopwood, Kim M Hemsley
Mucopolysaccharidosis type IIIA (MPS IIIA) is predominantly a disorder of the central nervous system, caused by a deficiency of sulfamidase (SGSH) with subsequent storage of heparan sulfate-derived oligosaccharides. No widely available therapy exists, and for this reason, a mouse model has been utilized to carry out a preclinical assessment of the benefit of intraparenchymal administration of a gene vector (AAVrh10-SGSH-IRES-SUMF1) into presymptomatic MPS IIIA mice. The outcome has been assessed with time, measuring primary and secondary storage material, neuroinflammation, and intracellular inclusions, all of which appear as the disease progresses...
May 2016: Human Gene Therapy
https://www.readbyqxmd.com/read/26956723/anesthetic-care-and-perioperative-complications-in-children-with-sanfilipo-syndrome-type-a
#15
Elif C Cingi, David S Beebe, Chester B Whitley, Kumar G Belani
BACKGROUND: Patients with mucopolysaccharidoses (MPS) are generally considered high risk for anesthesia care, owing to disease-related factors. Sanfilippo syndrome type A (MPS IIIA) is the most frequently occurring MPS. Anesthesia-specific information for MPS IIIA is not readily available in the literature. OBJECTIVES: To report post hoc analyses on anesthesia care and outcomes from a 2-year study of the natural history of patients with untreated MPS IIIA (NCT01047306)...
May 2016: Paediatric Anaesthesia
https://www.readbyqxmd.com/read/26918231/the-neurobehavioral-phenotype-in-mucopolysaccharidosis-type-iiib-an-exploratory-study
#16
E Shapiro, K King, A Ahmed, K Rudser, R Rumsey, B Yund, K Delaney, I Nestrasil, C Whitley, M Potegal
OBJECTIVES: Our goal was to describe the neurobehavioral phenotype in mucopolysaccharidosis Type IIIB (MPS IIIB). Parents report that behavioral abnormalities are a major problem in MPS III posing serious challenges to parenting and quality-of-life for both patient and parent. Our previous research on MPS IIIA identified autistic symptoms, and a Klüver-Bucy-type syndrome as indicated by reduced startle and loss of fear associated with amygdala atrophy. We hypothesized that MPS IIIB would manifest similar attributes when assessed with the same neurobehavioral protocol...
March 1, 2016: Molecular Genetics and Metabolism Reports
https://www.readbyqxmd.com/read/26710524/-sanfilippo-syndrome
#17
REVIEW
L A Osipova, L M Kuzenkova, L S Namazova-Baranova, A K Gevorkyan, T V Podkletnova, N D Vashakmadze
Sanfilippo syndrome (mucopolysaccharidosis type III) is a lysosomal disorder caused by a defect in the catabolism of heparan sulfate. Mucopolysaccharidosis type III is the most common type of all mucopolysaccharidoses. The pathogenic basis of the disease consists of the storage of undegraded substrate in the central nervous system. Progressive cognitive decline resulting in dementia and behavioural abnormalities are the main clinical characteristics of Sanfilippo syndrome. Mucopolysaccharidosis type III may be misdiagnosed as otherforms of developmental delay, attention deficit/hyperactivity disorder and autistic spectrum disorders because of lack of somatic symptoms, presence of mild and atypical forms of the disease...
2015: Vestnik Rossiĭskoĭ Akademii Meditsinskikh Nauk
https://www.readbyqxmd.com/read/26674264/mucopolysaccharidosis-iiib-confers-enhanced-neonatal-intracranial-transduction-by-aav8-but-not-by-5-9-or-rh10
#18
J A Gilkes, M D Bloom, C D Heldermon
Sanfilippo syndrome type B (mucopolysaccharidosis IIIB, MPS IIIB) is a lysosomal storage disease resulting from deficiency of N-acetyl-glucosaminidase (NAGLU) activity. To determine the possible therapeutic utility of recombinant adeno-associated virus (rAAV) in early gene therapy-based interventions, we performed a comprehensive assessment of transduction and biodistribution profiles of four central nervous system (CNS) administered rAAV serotypes, -5, -8, -9 and -rh10. To simulate optimal earliest treatment of the disease, each rAAV serotype was injected into the CNS of neonatal MPS IIIB and control animals...
March 2016: Gene Therapy
https://www.readbyqxmd.com/read/26670819/the-optimal-hemodynamics-management-of-post-cardiac-arrest-shock
#19
REVIEW
Tommaso Pellis, Filippo Sanfilippo, Giuseppe Ristagno
Patients resuscitated from cardiac arrest develop a pathophysiological state named "post-cardiac arrest syndrome." Post-resuscitation myocardial dysfunction is a common feature of this syndrome, and many patients eventually die from cardiovascular failure. Cardiogenic shock accounts for most deaths in the first 3 days, when post-resuscitation myocardial dysfunction peaks. Thus, identification and treatment of cardiovascular failure is one of the key therapeutic goals during hospitalization of post-cardiac arrest patients...
December 2015: Best Practice & Research. Clinical Anaesthesiology
https://www.readbyqxmd.com/read/26666772/incentives-for-starting-small-companies-focused-on-rare-and-neglected-diseases
#20
Sean Ekins, Jill Wood
Starting biotech or pharmaceutical companies is traditionally thought to be based around a scientist, their technology platform or a clinical candidate spun out from another company. Between us we have taken a different approach and formed two small early stage companies after initially leveraging the perspective of a parent with a child with a life-threatening rare disease. Phoenix Nest ( http://www.phoenixnestbiotech.com/ ) was co-founded to work on treatments for Sanfilippo syndrome a devastating neurodegenerative lysosomal storage disorder...
April 2016: Pharmaceutical Research
keyword
keyword
106261
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"